Nuformix plc (LON:NFX – Get Free Report)’s share price fell 11.8% on Wednesday . The company traded as low as GBX 0.13 and last traded at GBX 0.14. 27,570,943 shares were traded during trading, a decline of 10% from the average session volume of 30,772,732 shares. The stock had previously closed at GBX 0.16.
Nuformix Trading Up 2.3%
The stock has a market capitalization of £3.44 million, a P/E ratio of -4.51 and a beta of 1.54. The company has a 50-day moving average price of GBX 0.17 and a two-hundred day moving average price of GBX 0.20.
Nuformix (LON:NFX – Get Free Report) last announced its earnings results on Thursday, May 28th. The company reported GBX (0.02) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Featured Articles
- Five stocks we like better than Nuformix
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
